Clene Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CLNN Nasdaq 8731 https://clene.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Clene Inc.

Clene Appoints Neurology Expert to Executive Team - Mar 16th, 2023 1:46 pm
Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights - Mar 13th, 2023 11:00 am
CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial - Mar 9th, 2023 11:30 am
Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial - Mar 8th, 2023 9:10 pm
Clene Nanomedicine to Participate in Roth’s 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series - Mar 7th, 2023 1:00 pm
New Data Show CNM-Au8® Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial - Mar 6th, 2023 12:00 pm
Clene Announces Updated VISIONARY-MS Phase 2 Trial Data Presented at 2023 ACTRIMS Forum Show CNM-Au8® Demonstrated Significant Improvements in Clinical Outcomes, Brain Structure, and Visual System - Feb 27th, 2023 12:00 pm
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity - Feb 13th, 2023 12:00 pm
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23 - Jan 11th, 2023 1:00 pm
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg - Dec 27th, 2022 9:01 pm
Clene Announces Closing of $5 Million Debt Facility from the State of Maryland - Dec 12th, 2022 1:00 pm
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies - Nov 28th, 2022 1:00 pm
Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights - Nov 7th, 2022 1:00 pm
Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland - Oct 31st, 2022 12:00 pm
Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial - Oct 3rd, 2022 12:00 pm
Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3 - Sep 30th, 2022 8:12 pm
Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference - Sep 21st, 2022 11:00 am
Clene to Present at Upcoming September Investor Conferences - Aug 30th, 2022 11:00 am
Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis - Aug 15th, 2022 11:00 am
Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights - Aug 15th, 2022 11:00 am